Targeting the Basic Defect of Cystic Fibrosis: Breathe

The Breathe (Basic Research and Therapy) research program aims to use the knowledge acquired from the discovery of the gene responsible for cystic fibrosis to develop new treatments targeting the basic defect in CF.

Research teams led by Dr. Christine Bear (The Hospital for Sick Children, Toronto) and Dr. John Hanrahan (McGill University, Montreal) have been looking for molecules, including known drugs and natural products, which could correct the basic defect in cystic fibrosis. Both teams have identified a number of molecules which might serve as ‘correctors’ in cystic fibrosis cells. The teams are now investigating whether the most promising molecules can be developed into new therapies.

For details, read the Breathe Final Report

The SickKids Breathe Program (2004-2009): translating discovery to the patient

Help us fund important projects like this. Donate now!

Reviewed/updated: 2010-02-12